Cargando…

The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring

The expanded availability of adalimumab products continues to widen patient access and reduce costs with substantial benefit to healthcare systems. However, the long-term success of these medicines is highly dependent on maintaining consistency in quality, safety and efficacy while minimizing any ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wadhwa, Meenu, Bird, Chris, Atkinson, Eleanor, Cludts, Isabelle, Rigsby, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082443/ https://www.ncbi.nlm.nih.gov/pubmed/33936049 http://dx.doi.org/10.3389/fimmu.2021.636420

Ejemplares similares

The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab
por: Jia, Haiyan, et al.
Publicado: (2021)

Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab
por: Cludts, Isabelle, et al.
Publicado: (2017)

Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): Report of an international collaborative study
por: Wadhwa, Meenu, et al.
Publicado: (2015)

The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity
por: Metcalfe, Clive, et al.
Publicado: (2018)

International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab
por: Prior, Sandra, et al.
Publicado: (2017)

Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study
por: McDonald, Jacqueline U., et al.
Publicado: (2018)

Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard
por: Guan, Lidong, et al.
Publicado: (2023)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis
por: Chen, Zena, et al.
Publicado: (2021)

Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody
por: Mattiuzzo, Giada, et al.
Publicado: (2019)

IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs
por: Jia, Haiyan, et al.
Publicado: (2016)

The impact of thioredoxin reduction of allosteric disulfide bonds on the therapeutic potential of monoclonal antibodies
por: Gurjar, Shalom A., et al.
Publicado: (2019)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

A Case of Adalimumab-Induced Granulomatous Interstitial Nephritis
por: Plant, Rory, et al.
Publicado: (2021)

Restoration of Default Blood Monocyte-Derived Macrophage Polarization With Adalimumab But Not Etanercept in Rheumatoid Arthritis
por: Paoletti, Audrey, et al.
Publicado: (2022)

Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG
por: Rijpkema, Sjoerd, et al.
Publicado: (2018)

Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab
por: Chen, Peng-Yu, et al.
Publicado: (2023)

Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human
por: Wilmot, Helen V., et al.
Publicado: (2018)

Establishment of the World Health Organization 2(nd) International Standard for Factor XI, Plasma, Human
por: Wilmot, Helen, et al.
Publicado: (2017)

Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
por: Kato, Masaichi, et al.
Publicado: (2021)

Establishment of a WHO Reference Reagent for anti-Mullerian hormone
por: Ferguson, Jackie, et al.
Publicado: (2020)

Accuracy of the new rapid test for monitoring adalimumab levels
por: Rocha, Cátia, et al.
Publicado: (2019)

Neutrophils: Need for Standardized Nomenclature
por: McKenna, Ellen, et al.
Publicado: (2021)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization
por: Gils, Ann, et al.
Publicado: (2014)

Adalimumab-induced Anti-neutrophilic Cytoplasmic Antibody Vasculitis: A Rare Complication of an Increasingly Common Treatment
por: Chandra, Tanya, et al.
Publicado: (2019)

Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19
por: Patel, Serena, et al.
Publicado: (2021)

Case report: Safety and efficacy of adalimumab in treating difficult-to-treat rheumatoid arthritis in a human immunodeficiency virus-positive patient, one year follow-up
por: Chen, Jing-Wen, et al.
Publicado: (2022)

Development of a standardized and validated flow cytometry approach for monitoring of innate myeloid immune cells in human blood
por: van der Pan, Kyra, et al.
Publicado: (2022)

Standardization of neutrophil CD64 and monocyte HLA-DR measurement and its application in immune monitoring in kidney transplantation
por: Peng, Bo, et al.
Publicado: (2022)

A Comprehensive Review on Natural Bioactive Compounds and Probiotics as Potential Therapeutics in Food Allergy Treatment
por: Pratap, Kunal, et al.
Publicado: (2020)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015
por: Chan, Edward K. L., et al.
Publicado: (2015)

Commutability of Cytomegalovirus WHO International Standard in Different Matrices
por: Jones, Sara, et al.
Publicado: (2016)

Low Percentage of Signal Regulatory Protein α/β(+) Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients
por: Magill, Laura, et al.
Publicado: (2018)

GPR35 acts a dual role and therapeutic target in inflammation
por: Wu, Yetian, et al.
Publicado: (2023)

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?
por: Ravlić, Sanda, et al.
Publicado: (2022)

Adalimumab: a Treatment Option for Pyoderma Gangrenosum After Failure of Systemic Standard Therapies
por: Hinterberger, Louisa, et al.
Publicado: (2012)

A Dual Marker for Monitoring MDR-TB Treatment: Host-Derived miRNAs and M. tuberculosis-Derived RNA Sequences in Serum
por: Carranza, Claudia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_61gd9b15a4ge3qv8ufugpoqg8g